About
Hera Biotech is a pioneering women's health diagnostics company building AI-powered, non-invasive tissue-based tests that address two of the most underdiagnosed conditions globally: endometriosis and cervical cancer. Backed by over 20 billion data points, 1,000+ clinical samples, and four proprietary datasets, Hera's platform delivers diagnostic accuracy that matches or exceeds current surgical gold standards—without the invasiveness, delays, or costs. Their flagship product, MetriDx™, is a non-invasive molecular test for endometriosis detection and staging, designed to replace laparoscopic surgery as the diagnostic standard. It delivers results in days with high specificity. HERAfem™ is a point-of-care cervical cancer diagnostic device for detecting CIN1+ lesions, boasting a high negative predictive value and built for deployment in low-resource and global markets. Hera's platform integrates seamlessly into OB-GYN practices, fertility clinics, and drug discovery pipelines. With 8 patents across molecular and physical detection methods, commercial access secured in Latin America (2026), and expansion planned across Asia and Africa (2027), Hera is positioning itself as a global leader in accessible, equitable women's health diagnostics. The company's team includes clinicians and doctoral-level experts among its investors, ensuring strong alignment between scientific rigor and real-world clinical utility.
Key Features
- MetriDx™ Endometriosis Test: A non-invasive molecular diagnostic test for endometriosis detection and staging, designed to replace surgical laparoscopy with results delivered in days.
- HERAfem™ Cervical Cancer Diagnostic: A point-of-care device for detecting CIN1+ cervical lesions with a high negative predictive value, deployable in clinical and low-resource settings globally.
- AI-Powered Diagnostic Platform: Fueled by 20 billion data points, 1,000+ samples, and 4 proprietary datasets, the platform provides high specificity and accuracy beyond current diagnostic standards.
- Seamless Clinical Integration: Designed to integrate directly into OB-GYN, fertility, and drug discovery workflows without disrupting existing care pathways.
- Global Market Access: HERAfem™ is launching in Latin America in 2026, with Asia and Africa planned for 2027, supported by reimbursement pathways already in motion.
Use Cases
- OB-GYN clinicians using MetriDx™ to detect and stage endometriosis without requiring surgical laparoscopy, reducing patient wait times from years to days.
- Fertility clinics integrating Hera's platform to improve diagnostic accuracy for endometriosis before initiating assisted reproductive treatments.
- Point-of-care cervical cancer screening in low-resource or remote clinical settings using HERAfem™ to detect CIN1+ lesions affordably and quickly.
- Pharmaceutical and biotech companies leveraging Hera's diagnostic platform and datasets in drug discovery workflows targeting gynecologic conditions.
- Healthcare systems in Latin America, Asia, and Africa adopting HERAfem™ to close the cervical cancer diagnostic gap in underserved populations.
Pros
- Non-Invasive and Fast: Eliminates the need for invasive surgical procedures; MetriDx™ delivers results in days versus the years-long diagnostic delays currently experienced by patients.
- Strong Scientific Foundation: Backed by 8 patents, 20B+ data points, and a team that includes clinicians and doctoral-level expert investors, ensuring high credibility and accuracy.
- Globally Scalable: Point-of-care design and cost-efficient deployment model make Hera's diagnostics accessible in both high-income and low-resource markets worldwide.
- Clinician Validated: Products have been selected by top OB-GYN and fertility clinics, confirming real-world clinical demand and readiness.
Cons
- Limited Current Availability: Commercial availability is still rolling out—HERAfem™ launches in Latin America in 2026, with broader global access in 2027, limiting near-term reach.
- Narrow Diagnostic Focus: The platform currently addresses only two conditions—endometriosis and cervical cancer—which may limit appeal for broader gynecologic diagnostics needs.
- Reimbursement Pathways Still Developing: While reimbursement pathways are in motion, they are not yet fully established, which may create adoption friction in some markets.
Frequently Asked Questions
What conditions does Hera Biotech's platform diagnose?
Hera Biotech's platform currently focuses on two conditions: endometriosis (via MetriDx™) and cervical cancer or pre-cancerous lesions (via HERAfem™).
How is MetriDx™ different from traditional endometriosis diagnosis?
MetriDx™ is a non-invasive molecular test that replaces laparoscopic surgery—the current gold standard—with a tissue-based diagnostic that delivers results in days, not years.
Where is HERAfem™ currently available?
HERAfem™ is commercially launching across Latin America in 2026, with expansion into Asia and Africa planned for 2027.
What data powers Hera Biotech's AI platform?
The platform is trained on over 20 billion data points, more than 1,000 clinical samples, and four proprietary datasets focused on gynecologic diagnostics.
Who are Hera Biotech's products designed for?
Hera's diagnostics are designed for OB-GYN practitioners, fertility clinics, and drug discovery teams seeking faster, more accurate, and less invasive diagnostic tools for women's health.
